Please ensure Javascript is enabled for purposes of website accessibility

GlaxoSmithKline Re-Teams With Chinese Biotech For COVID-19 Vaccine

By Eric Volkman - Apr 5, 2020 at 12:14PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It is the latest in a series of collaborations between the big pharmaceutical company and entities researching potential vaccines for the disease.

Opening up yet another front in the war against COVID-19, the disease caused by the fast-spreading SARS-CoV-2 coronavirus, GlaxoSmithKline (GSK -0.17%) announced it is contributing to another vaccine research effort.

The UK-based pharmaceutical giant wrote, in an update on its work combating the coronavirus and the disease, that it is collaborating with Xiamen Innovax Biotech. The China-based company is attempting to develop a COVID-19 vaccine.

A coronavirus colony.

Image source: Getty Images.

That candidate, known as COVID-19 XWG-03, is being developed by Innovax in conjunction with researchers from Xiamen University. GlaxoSmithKline says its role in the project will be to provide access to an adjuvant for use in the vaccine. Adjuvants, a specialty of GlaxoSmithKline, are additives used in certain vaccines to boost the body's immune response to the relevant threat.

This is not the first collaboration between the two companies. In 2019 they teamed up to develop a vaccine for human papillomavirus (HPV), a virus that can cause cancer. This work was to feed into GlaxoSmithKline's efforts to devise a successor to its HPV treatment, Cervarix.

Although GlaxoSmithKline is one of the top vaccine makers among the world's pharmaceutical companies, it has elected to take a largely secondary role in the development of COVID-19 vaccines. Innovax is only its most recently announced partner in these efforts -- it is also providing adjuvant technology for several other research organizations and companies; among the latter is China-based Clover Biopharmaceuticals.

On Friday, GlaxoSmithKline's share price dipped by 1.5%, more or less in line with the broader stock market indexes on that day.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GSK Stock Quote
GSK
GSK
$34.25 (-0.17%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
394%
 
S&P 500 Returns
127%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.